GSK PLC Sponsored ADR (GSK) To Go Ex-Dividend on May 15th

GSK PLC Sponsored ADR (NYSE:GSK – Get Free Report) declared a quarterly dividend on Wednesday, April 29th. Shareholders of record on Friday, May 15th will be paid a dividend of 0.44 per share by the pharmaceutical company on Thursday, July 9th. This represents a c) annualized dividend and a yield of 3.5%. The ex-dividend date of this dividend is Friday, May 15th.

GSK has decreased its dividend by an average of 0.1%per year over the last three years. GSK has a payout ratio of 37.4% meaning its dividend is sufficiently covered by earnings. Equities analysts expect GSK to earn $5.13 per share next year, which means the company should continue to be able to cover its $1.81 annual dividend with an expected future payout ratio of 35.3%.

Get GSK alerts:

GSK Stock Up 2.2%

GSK opened at $50.89 on Wednesday. The company has a market capitalization of $103.26 billion, a PE ratio of 13.22, a price-to-earnings-growth ratio of 2.53 and a beta of 0.38. The company has a debt-to-equity ratio of 0.80, a current ratio of 0.79 and a quick ratio of 0.52. GSK has a fifty-two week low of $35.45 and a fifty-two week high of $61.69. The business has a 50-day moving average of $54.74 and a 200-day moving average of $52.00.

Analyst Ratings Changes

Several brokerages recently weighed in on GSK. Barclays reaffirmed an “underweight” rating on shares of GSK in a research report on Friday, February 20th. Weiss Ratings upgraded shares of GSK from a “hold (c+)” rating to a “buy (b)” rating in a report on Friday, May 1st. Morgan Stanley reaffirmed an “underweight” rating on shares of GSK in a research note on Wednesday, January 14th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating on shares of GSK in a report on Friday, January 16th. Finally, TD Cowen restated a “hold” rating on shares of GSK in a report on Monday, February 9th. Two equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and three have issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Reduce” and an average target price of $53.00.

Check Out Our Latest Research Report on GSK

GSK Company Profile

(Get Free Report)

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing.

Further Reading

• Five stocks we like better than GSK
• Ally Financial Is Back to Basics—And Investors Are Watching
• Navitas Breaks Out on India Deal, Validating High-Power AI Pivot
• Navy Catalyst Ignites Odysight’s Growth Engine
• AST SpaceMobile Plummets on Galactic Q1 Miss: Can Vertical Integration Save the SpaceX Rival?

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.